FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris

Roche announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation status to MabThera/Rituxan ® (rituximab) for pemphigus vulgaris, a rare, serious and life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news